Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,097 Million (Small Cap)
20.00
NA
7.55%
-0.20
7.02%
1.82
Revenue and Profits:
Net Sales:
572 Million
(Quarterly Results - Mar 2026)
Net Profit:
107 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.41%
0%
5.41%
6 Months
2.63%
0%
2.63%
1 Year
15.08%
0%
15.08%
2 Years
4.46%
0%
4.46%
3 Years
-1.82%
0%
-1.82%
4 Years
14.15%
0%
14.15%
5 Years
33.46%
0%
33.46%
Yabao Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.21%
EBIT Growth (5y)
5.75%
EBIT to Interest (avg)
20.35
Debt to EBITDA (avg)
0.20
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.87
Tax Ratio
22.17%
Dividend Payout Ratio
88.24%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.87%
ROE (avg)
5.84%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.63
EV to EBIT
15.65
EV to EBITDA
10.22
EV to Capital Employed
1.77
EV to Sales
1.72
PEG Ratio
1.08
Dividend Yield
5.08%
ROCE (Latest)
11.28%
ROE (Latest)
8.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
572.00
531.40
7.64%
Operating Profit (PBDIT) excl Other Income
127.00
57.40
121.25%
Interest
0.20
0.40
-50.00%
Exceptional Items
-14.10
17.90
-178.77%
Consolidate Net Profit
107.00
101.40
5.52%
Operating Profit Margin (Excl OI)
222.00%
44.10%
17.79%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 7.64% vs -6.66% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 5.52% vs 335.19% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,223.30
2,668.50
-16.68%
Operating Profit (PBDIT) excl Other Income
453.10
424.30
6.79%
Interest
1.80
5.70
-68.42%
Exceptional Items
-38.50
-25.90
-48.65%
Consolidate Net Profit
299.90
223.90
33.94%
Operating Profit Margin (Excl OI)
143.10%
106.10%
3.70%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -16.68% vs -7.67% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 33.94% vs 24.46% in Dec 2024
About Yabao Pharmaceutical Group Co., Ltd. 
Yabao Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






